A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

被引:116
|
作者
Charpentier, B [1 ]
Rostaing, L
Berthoux, F
Lang, P
Civati, G
Touraine, JL
Squifflet, JP
Vialtel, P
Abramowicz, D
Mourad, G
Wolf, P
Cassuto, E
Moulin, B
Rifle, G
Pruna, A
Merville, P
Mignon, F
Legendre, C
Le Pogamp, P
Lebranchu, Y
Toupance, O
de Ligny, BH
Touchard, G
Olmer, M
Purgus, R
Pouteil-Noble, C
Glotz, D
Bourbigot, B
Leski, M
Wauters, JP
Kessler, M
机构
[1] Hop Bicetre, Serv Nephrol, Le Kremlin Bicetre, France
[2] CHU Toulouse, Hop Rangueil, Unite Transplantat Organes, Toulouse, France
[3] Hop Nord St Etienne, Serv Nephrol & Transplantat, St Etienne, France
[4] Hop Henri Mondor, Serv Nephrol, F-94010 Creteil, France
[5] Azienda Osped Osped Niguarda Ca Granda, Div Nefrol & Dialisi, Milan, Italy
[6] Hop Edouard Herriot, Serv Transplantat & Immunol Clin, Lyon, France
[7] Clin Univ St Luc, Serv Transplantat Renale & Chirurg Glandes Endocr, B-1200 Brussels, Belgium
[8] CHU Nord, Hop Michallon, Serv Nephrol & Transplanatat, Grenoble, France
[9] Clin Univ Hop Erasme, Dept Nephrol, Brussels, Belgium
[10] Hop Lapeyronie, Serv Chirurg Gen & Transplantat, F-34059 Montpellier, France
[11] Hop Hautepierre, Serv Chirurg Gen & Transplantat Multiorganes, Strasbourg, France
[12] Hop Louis Pasteur, Serv Nephrol, Nice, France
[13] Hop Civil, Serv Nephrol & Hemodialyse, Strasbourg, France
[14] Hop Bocage, Serv Nephrol & Reanimat Metab, Dijon, France
[15] CHU Amiens, Hop Sud, Serv Nephrol, Amiens, France
[16] Hop Pellegrin, Serv Nephrol, F-33076 Bordeaux, France
[17] Hop Bichat Claude Bernard, Serv Nephrol, Paris, France
[18] Hop St Louis, Serv Nephrol, Paris, France
[19] CHU Pontchaillou, Serv Nephrol, Rennes, France
[20] Hop Bretonneau, Serv Nephrol, Tours, France
[21] Hop Maison Blanche, Serv Nephrol, Reims, France
[22] Hop Clemenceau, Serv Nephrol & Hemodialyse, Caen, France
[23] Cite Hosp Miletrie, Poitiers, France
[24] Hop Conception, Serv Nephrol & Hemodialyse, Marseille, France
[25] Ctr Hosp Lyon Sud, Serv Nephrol, F-69310 Pierre Benite, France
[26] Hop Georges Pompidou, Serv Nephrol, Paris, France
[27] Hop Cavale Blanche, Serv Nephrol, Brest, France
[28] Univ Geneva, Hop Cantonal, Div Nephrol, Dept Med, CH-1211 Geneva, Switzerland
[29] CHU Vaudois, Div Nephrol, Dept Med, CH-1011 Lausanne, Switzerland
[30] CHU Nancy, Hop Brabois, Serv Nephrol & Transplantat, Vandoeuvre Les Nancy, France
关键词
D O I
10.1097/01.TP.0000056635.59888.EF
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients. Methods. In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n= 186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine, and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy. Results. Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05). Conclusions. Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 50 条
  • [41] ANTITHYMOCYTE GLOBULIN FOR STEROID RESISTANT REJECTION IN RENAL-TRANSPLANT RECIPIENTS IMMUNOSUPPRESSED WITH TRIPLE THERAPY
    RICHARDSON, AJ
    HIGGINS, RM
    LIDDINGTON, M
    MURIE, J
    TING, A
    MORRIS, PJ
    TRANSPLANT INTERNATIONAL, 1989, 2 (01) : 27 - 32
  • [42] Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression
    Sonmez, Ozge
    Ozcan, Seyda Gul
    Karaca, Cebrail
    Atli, Zeynep
    Dincer, Mevlut Tamer
    Trabulus, Sinan
    Seyahi, Nurhan
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2024, 22 (04) : 270 - 276
  • [43] Antithymocyte globulin induction therapy for adult heart transplantation: A UK national study
    Emin, Akan
    Rogers, Chris A.
    Thekkudan, Joyce
    Bonser, Robert S.
    Banner, Nicholas R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (07): : 770 - 777
  • [44] Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults
    Zhu, Xianmin
    Guan, Jun
    Xu, Jinhuan
    Wei, Jia
    Jiang, Lijun
    Yin, Jin
    Zhao, Lei
    Zhang, Yicheng
    BLOOD CELLS MOLECULES AND DISEASES, 2014, 53 (03) : 157 - 160
  • [45] Sirolimus plus Tacrolimus Maintenance with No Induction Therapy May Maximize Survival in Lung Transplant Recipients
    Wijesinha, M.
    Hirshon, J.
    Terrin, M.
    Magder, L.
    Brown, C.
    Stafford, K.
    Iacono, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S122 - S123
  • [46] Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study
    Park, Jae Berm
    Kim, Sung-Joo
    Oh, Ha Young
    Han, Young Seok
    Kim, Doo Jin
    Park, Jin Wan
    Kwon, Choon Hyuck
    Joh, Jae-Won
    Lee, Suk-Koo
    TRANSPLANT INTERNATIONAL, 2006, 19 (06) : 478 - 484
  • [47] Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients
    Varghese, Z
    Abudher, MN
    Fernando, ON
    Moorhead, JF
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (03) : 2251 - 2253
  • [48] Clinical Experience With Thymoglobulin and Antithymocyte Globulin-Fresenius as Induction Therapy in Renal Transplant Patients: A Retrospective Study
    Cicora, Federico
    Mos, Fernando
    Paz, Marta
    Roberti, Javier
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2013, 11 (05) : 418 - 422
  • [49] Evaluation of Published Population Pharmacokinetic Models to Inform Tacrolimus Therapy in Adult Lung Transplant Recipients
    Kirubakaran, Ranita
    Singh, Rani M.
    Carland, Jane E.
    Day, Richard O.
    Stocker, Sophie L.
    THERAPEUTIC DRUG MONITORING, 2024, 46 (04) : 434 - 445
  • [50] Favorable results of concomitant tacrolimus and sirolimus therapy in Taiwanese renal transplant recipients at 12 months
    Chen, Kuo-Hsin
    Tsai, Meng-Kun
    Lai, I-Rue
    Wu, Fe-Lin Lin
    Hu, Rey-Heng
    Lee, Po-Huang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (07) : 533 - 539